Literature DB >> 15334669

Inhibitory effect of ubiquitin-proteasome pathway on proliferation of esophageal carcinoma cells.

Wei-Guo Zhang1, Jie-Ping Yu, Qing-Ming Wu, Qiang Tong, Sheng-Bao Li, Xiao-Hu Wang, Guo-Jian Xie.   

Abstract

AIM: To investigate the inhibitory effect of ubiquitin-proteasome pathway (UPP) on proliferation of esophageal carcinoma cells.
METHODS: Esophageal carcinoma cell strain EC9706 was treated with MG-132 to inhibit its UPP specificity. Cell growth suppression was evaluated with 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. DNA synthesis was evaluated by (3)H-thymidine ((3)H-TdR) incorporation. Morphologic changes of cells were observed under microscope. Activity of telomerase was examined by telomeric repeat amplification protocol (TRAP) of PCR-ELISA. Cell cycle and apoptosis were detected by flow cytometry (FCM). DNA fragment analysis was used to confirm the presence of apoptosis. Expression of p27(kip1) was detected by immunocytochemical technique.
RESULTS: After exposed to MG-132, the growth and value of (3)H-TdR incorporation of EC9706 cells were obviously inhibited. Cells became round, small and exfoliative under microscope. TRAP PCR-ELISA showed that light absorption of cells gradually decreased after exposed to 5 micromol/L of MG-132 for 24, 48, 72 and 96 h (P<0.01). The percentage of cells at G(0)/G(1) phase was increased and that at S and G(2)/M was decreased (P<0.01). The rate of apoptotic cells treated with 5 micromol/L of MG-132 for 48 and 96 h was 31.7% and 66.4%, respectively. Agarose electrophoresis showed marked ladders. In addition, the positive signals of p27(kip1) were located in cytoplasm and nuclei in MG-132 group in contrast to cytoplasm staining in control group.
CONCLUSION: MG-132 can obviously inhibit proliferation of EC9706 cells and induce apoptosis. The mechanisms include upregulation of p27(kip1) expression, G(1) arrest and depression of telomerase activity. The results indicate that inhibiting UPP is a novel strategy for esophageal carcinoma therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15334669      PMCID: PMC4572101          DOI: 10.3748/wjg.v10.i19.2779

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  33 in total

1.  c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells.

Authors:  M A Gregory; S R Hann
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

2.  Growth inhibition of human glioma cells by transfection-induced P21 and its effects on telomerase activity.

Authors:  K Harada; K Kurisu; T Sadatomo; H Tahara; E Tahara; T Ide; E Tahara
Journal:  J Neurooncol       Date:  2000-03       Impact factor: 4.130

Review 3.  Plant development: regulation by protein degradation.

Authors:  Hanjo Hellmann; Mark Estelle
Journal:  Science       Date:  2002-08-02       Impact factor: 47.728

4.  Loss of p27(KIP1) expression predicts poor prognosis in patients with esophageal squamous cell carcinoma.

Authors:  A Shamma; Y Doki; T Tsujinaka; H Shiozaki; M Inoue; M Yano; K Kawanishi; M Monden
Journal:  Oncology       Date:  2000-02       Impact factor: 2.935

5.  Potential of the proteasomal inhibitor MG-132 as an anticancer agent, alone and in combination.

Authors:  D Banerjee; A Liefshitz
Journal:  Anticancer Res       Date:  2001 Nov-Dec       Impact factor: 2.480

6.  p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest.

Authors:  K Polyak; J Y Kato; M J Solomon; C J Sherr; J Massague; J M Roberts; A Koff
Journal:  Genes Dev       Date:  1994-01       Impact factor: 11.361

7.  PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis.

Authors:  Yi-He Ling; Leonard Liebes; Bruce Ng; Michael Buckley; Peter J Elliott; Julian Adams; Jian-Dong Jiang; Franco M Muggia; Roman Perez-Soler
Journal:  Mol Cancer Ther       Date:  2002-08       Impact factor: 6.261

8.  Cyclin dependent kinase inhibitor p27(Kip1) is upregulated by hypoxia via an ARNT dependent pathway.

Authors:  Gang Wang; Richard Reisdorph; Robert E Clark; Robin Miskimins; Ronald Lindahl; W Keith Miskimins
Journal:  J Cell Biochem       Date:  2003-10-15       Impact factor: 4.429

9.  MG-132, an inhibitor of proteasomes and calpains, induced inhibition of oocyte maturation and aneuploidy in mouse oocytes.

Authors:  John B Mailhes; Colette Hilliard; Mary Lowery; Steve N London
Journal:  Cell Chromosome       Date:  2002-10-08

10.  Increased expression of the ubiquitin-proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-kappaB.

Authors:  A S Whitehouse; M J Tisdale
Journal:  Br J Cancer       Date:  2003-09-15       Impact factor: 7.640

View more
  5 in total

1.  Effect of silencing of high mobility group A2 gene on gastric cancer MKN-45 cells.

Authors:  Chun-Hui Wei; Li-Xiu Wei; Ming-Yu Lai; Jia-Zhuang Chen; Xi-Jing Mo
Journal:  World J Gastroenterol       Date:  2013-02-28       Impact factor: 5.742

2.  Effect of p27mt gene on apoptosis of the colorectal cancer cell line Lovo.

Authors:  Jun Chen; Wu-Hua Ding; Shao-Yong Xu; Jia-Ning Wang; Yong-Zhang Huang; Chang-Sheng Deng
Journal:  World J Gastroenterol       Date:  2009-06-14       Impact factor: 5.742

3.  The Mechanistic Links Between Proteasome Activity, Aging and Age-related Diseases.

Authors:  Isabel Saez; David Vilchez
Journal:  Curr Genomics       Date:  2014-02       Impact factor: 2.236

4.  Identifying reproducible cancer-associated highly expressed genes with important functional significances using multiple datasets.

Authors:  Haiyan Huang; Xiangyu Li; You Guo; Yuncong Zhang; Xusheng Deng; Lufei Chen; Jiahui Zhang; Zheng Guo; Lu Ao
Journal:  Sci Rep       Date:  2016-10-31       Impact factor: 4.379

Review 5.  Protein clearance strategies for disease intervention.

Authors:  Franziska Hommen; Saygın Bilican; David Vilchez
Journal:  J Neural Transm (Vienna)       Date:  2021-10-23       Impact factor: 3.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.